All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
US FDA approves Roche’s Vabysmo PFS for three primary causes of vision loss
Designed to simplify administration, Vabysmo PFS is said to be the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness, providing a ready-to-use option for retina specialists
GSK, CureVac extend collaboration into €1.4bn licensing agreement
GSK will develop, manufacture and commercialise the vaccine candidates worldwide, and CureVac will receive €400m upfront and up to €1.05bn in development, regulatory and sales milestone payments and tiered royalties
Merck partners with Afrigen to boost mRNA vaccine technology
Merck, through its Life Science business sector, signed a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA vaccine technology platform
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Lilly gets FDA approval for Kisunla to treat early symptomatic AD
Kisunla, administered as a once-monthly 350mg/20mL IV injection, can help the body remove the excessive buildup of amyloid plaques, slow the decline, and result in lower treatment costs and fewer infusions
Moderna secures $176m BARDA project to produce bird-flu vaccine
The funding is intended to support late-stage development and licensure of an mRNA-based pre-pandemic vaccine against the H5 influenza virus, a subtype of influenza virus that causes a highly infectious, severe disease in birds (bird flu)
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition
Samsung Bioepis gets FDA approval for Stelara biosimilar Pyzchiva
The US FDA approved Pyzchiva for all indications of its reference medicine, based on a totality of evidence including analytical, non-clinical and clinical data showing biosimilarity to Stelara, with no variation in safety, purity, and potency
Neurocrine gets FDA priority review for crinecerfont to treat CAH
The US health regulator accepted the company’s two new drug applications (NDAs) for crinecerfont, an investigational therapy being developed for the treatment of CAH, as a capsule formulation and as an oral solution formulation
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins